bradycardie are also given to clients at risk to treat thrombosis. pulmonary embolism, and myocardial infarction...
bradycardie are also given to clients at risk to treat thrombosis. pulmonary embolism, and myocardial infarction and are for thromboembolism. the effects of this medication includes slowing 10. heart rate, decreasing cardiac output and contractility; decrease bronchoconstriction in resistance in pts with asthma or COPD; affect cardiac rhythm/automaticity (decrease sin conduction; increase refractory period in AV node); decrease systolic and diastolic B/P. onstriction, increased airway naticity (decrease sinus rate, SA/AV 11. A therapeutic dosage of does not dissolve clots; instead, it prevents formation of new thrombi, and normal activated partial thromboplastin time (APTT) is maintained at _ to times normal. is 12. The normal international normalized ratio (INR) is 1.00 to 1.30. A level of _ to__ maintained in standard warfarin therapy and a level of 3.0 to 4.5 in high-dose warfarin sodium (Coumadin) therapy. If the INR is below the recommended range, the dosage should be ; if it is above the recommended range, the dosage should be 13. is used early in the course of myocardial infarction (within 4 to 6 hours of onset); can restore blood flow, limit myocardial damage, preserve left ventricular function, and prevent death. 14. The antidote to "clot-busting" drugs is threatening conditions. ; used only in acute life- 15. this most commonly used cardiac glycosides increase the force of myocardial contractions and slow the heart rate. Monitor the client for signs of toxicity, including anorexia, nausea and vomiting, visual disturbances (e.g., diplopia, blurred vision, yellow-green halos),